PeopleBio, a company specializing in blood-based Alzheimer’s diagnostics, hit the upper price limit early in trading after receiving an "unqualified" opinion on its audit report.


[Market Focus] PeopleBio Hits Upper Price Limit on "Unqualified" Audit Opinion View original image

As of 9:47 a.m. on April 9, PeopleBio was trading at 1,271 won, up 29.96% (293 won) from the previous session.


On April 7, PeopleBio received an "unqualified" audit opinion from its external auditor for its previous fiscal year report. This outcome appears to have alleviated financial risks, boosting investor sentiment.



Additionally, the company acquired certification for meeting the requirements for venture status, and as a result, was reclassified from an investment warning category to the venture business sector as of the previous day.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing